NCT00421525 - Phase I/II Study of hLL1 in Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Multiple MyelomaMyeloma, Plasma-CellPLASMACYTOMA

Interventions

BIOLOGICAL

milatuzumab

twice weekly dosing for 4 weeks, total of 8 doses

Trial Locations (6)

New York Presbyterian Hospital/Cornell Medical Center, New York

Roswell Park Cancer Institute, Buffalo

Hospital University of Pennsylvania, Philadelphia

Winship Cancer Institute, Emory University, Atlanta

Center for Cancer Care, Goshen

Hackensack University Medical Center, Hackensack